These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30471053)

  • 41. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
    Lippi F; Capezzone M; Angelini F; Taddei D; Molinaro E; Pinchera A; Pacini F
    Eur J Endocrinol; 2001 Jan; 144(1):5-11. PubMed ID: 11174831
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden.
    Ciappuccini R; Hardouin J; Heutte N; Vaur D; Quak E; Rame JP; Blanchard D; de Raucourt D; Bardet S
    Eur J Endocrinol; 2014 Aug; 171(2):247-52. PubMed ID: 24866576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant human TSH versus hypothyroidism. Cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma.
    Dietlein M; Busemeyer S; Kobe C; Schmidt M; Theissen P; Schicha H
    Nuklearmedizin; 2010; 49(6):216-24. PubMed ID: 20877918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk Factors for Indeterminate Response After Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer.
    Jeong E; Yoon JK; Lee SJ; Soh EY; Lee J; An YS
    Clin Nucl Med; 2019 Sep; 44(9):714-718. PubMed ID: 31162260
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preparation for radioactive iodine therapy is not a risk factor for the development of hyponatremia in thyroid cancer patients.
    Kim J; Cho SG; Kang SR; Kwon SY; Cho DH; Cho JS; Song HC
    Medicine (Baltimore); 2017 Feb; 96(5):e6004. PubMed ID: 28151897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy.
    Luo H; Tobey A; Auh S; Cochran C; Zemskova M; Reynolds J; Lima C; Burman K; Wartofsky L; Skarulis M; Kebebew E; Klubo-Gwiezdzinska J
    Clin Endocrinol (Oxf); 2018 Oct; 89(4):481-488. PubMed ID: 29972703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors related to clinical hypothyroid severity in thyroid cancer patients after thyroid hormone withdrawal.
    Huang SC; Wu VC; Lin SY; Sheu WH; Song YM; Lin YH; Wu CC; Chang WD
    Thyroid; 2009 Jan; 19(1):13-20. PubMed ID: 19072673
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods.
    Vallejo Casas JA; Mena Bares LM; Gálvez MA; Marlowe RJ; Latre Romero JM; Martínez-Paredes M
    Nucl Med Commun; 2011 Sep; 32(9):840-6. PubMed ID: 21691237
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation.
    Iakovou I; Goulis DG; Tsinaslanidou Z; Giannoula E; Katsikaki G; Konstantinidis I
    Head Neck; 2016 Apr; 38 Suppl 1():E227-30. PubMed ID: 25537365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States.
    Wang TS; Cheung K; Mehta P; Roman SA; Walker HD; Sosa JA
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1672-80. PubMed ID: 20139234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 52. I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal.
    Hong CM; Kim CY; Son SH; Jung JH; Lee CH; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC
    Ann Nucl Med; 2017 Oct; 31(8):582-589. PubMed ID: 28677070
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients.
    Rosario PW; Xavier AC; Calsolari MR
    Thyroid; 2010 Nov; 20(11):1247-52. PubMed ID: 20950256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study.
    Seo GH; Kong KA; Kim BS; Kang SY; Moon BS; Yoon HJ; Kim HO
    J Clin Endocrinol Metab; 2021 Jun; 106(7):e2580-e2588. PubMed ID: 33755732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study.
    Luster M; Handkiewicz-Junak D; Grossi A; Zacharin M; Taïeb D; Cruz O; Hitzel A; Casas JA; Mäder U; Dottorini ME;
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3948-53. PubMed ID: 19773393
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.
    Fu H; Ma C; Tang L; Wu F; Liu B; Wang H
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):121-8. PubMed ID: 24844252
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
    Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
    Piccardo A; Puntoni M; Ferrarazzo G; Foppiani L; Bottoni G; Altrinetti V; Treglia G; Naseri M; Dib B; Cabria M; Trimboli P; Massollo M; Giovanella L
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1218-1223. PubMed ID: 29460027
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
    Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. INITIAL ADOPTION OF RECOMBINANT HUMAN THYROID-STIMULATING HORMONE FOLLOWING THYROIDECTOMY IN THE MEDICARE THYROID CANCER PATIENT POPULATION.
    Dinan MA; Li Y; Reed SD; Sosa JA
    Endocr Pract; 2019 Jan; 25(1):31-42. PubMed ID: 30383499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.